坐骨神经痛市场规模、份额和成长分析：按疾病类型、药物类别、给药途径、分销管道和地区 - 2025-2032 年行业预测

2023年全球坐骨神经痛市场规模为81.8亿美元，从2024年的86.5亿美元成长到2032年的134.7亿美元，在预测期间（2025-2032年）预计复合年增长率为5.7%。

预计未来几年全球坐骨神经痛市场将显着成长，这主要是由于与久坐生活方式、人口老化和脊椎疾病快速增加相关的坐骨神经痛病例数量不断增加。诊断技术和治疗方法的创新，提高了诊断的准确性和管理的有效性。此外，人们对早期疗育和復健需求的认识不断提高正在推动市场扩张。然而，挑战依然存在，包括高昂的治疗费用、某些地区先进医疗保健系统的使用机会有限以及与外科手术相关的风险。儘管存在这些障碍，但向微创技术的转变、新治疗药物的推出以及对个人化治疗解决方案日益增长的需求预计将推动全球坐骨神经痛市场的发展。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 技术评估
• 专利分析

坐骨神经痛市场规模：依疾病类型划分

• 市场概况
• 急性坐骨神经痛
• 慢性坐骨神经痛
• 其他的

坐骨神经痛市场规模：依药物类别

• 市场概况
• 非类固醇消炎剂
• 口服类固醇
• 抗惊厥药
• 三环抗忧郁药物
• 阿片类止痛药
• 其他的

坐骨神经痛市场规模：依给药途径划分

• 市场概况
• 口服
• 注射

坐骨神经痛市场规模：依分销管道分类

• 市场概况
• 医院药房
• 零售药房
• 网路药房

坐骨神经痛市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Medtronic plc（Ireland）
• Johnson & Johnson（USA）
• Zimmer Biomet Holdings, Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi SA（France）
• Novartis International AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Zynex Inc.（USA）
• Sorrento Therapeutics, Inc（USA）
• Hikma Pharmaceuticals PLC（UK）
• Viatris Inc.（USA）
• Boston Scientific Corporation（USA）
• Abbott Laboratories（USA）
• Stryker Corporation（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• Bristol-Myers Squibb Company（USA）

结论和建议

Global Sciatica Market size was valued at USD 8.18 billion in 2023 and is poised to grow from USD 8.65 billion in 2024 to USD 13.47 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global sciatica market is poised for substantial growth in the upcoming years, primarily due to a rise in sciatica cases linked to sedentary lifestyles, an aging demographic, and a surge in spinal disorders. Innovations in diagnostic technologies and treatment options are enhancing diagnosis accuracy and management effectiveness. Furthermore, heightened awareness of the need for early intervention and rehabilitation is propelling market expansion. However, challenges persist, including high treatment costs, restricted access to advanced healthcare systems in some areas, and risks associated with surgical procedures. Despite these hurdles, the shift toward minimally invasive techniques, the introduction of new therapeutics, and a growing appetite for personalized treatment solutions are anticipated to invigorate the global sciatica market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Market Segmental Analysis

Global Sciatica Market is segmented by Disease Type, Drug Class, Route of Administration, Distribution Channel and region. Based on Disease Type, the market is segmented into Acute Sciatica, Chronic Sciatica and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Market

A significant factor propelling the global sciatica market is the widespread lack of awareness and subsequent underdiagnosis of the condition. Contributing elements include sedentary lifestyles, poor posture, rising obesity rates, and an aging demographic, all of which have led to an increased prevalence of sciatica cases. As awareness grows and more individuals seek proper diagnosis and treatment, there is a heightened demand for effective diagnostic methods, therapeutic interventions, and pain management options. This growing need plays a crucial role in driving the overall expansion of the market and underscores the importance of addressing this overlooked health issue.

Restraints in the Global Sciatica Market

One significant challenge facing the global sciatica market is the prevalent lack of awareness and underdiagnosis associated with the condition. Many individuals experiencing sciatica symptoms are often unaware of their significance, which results in delayed medical intervention and treatment. Additionally, restricted access to healthcare services, particularly in rural regions, exacerbates the issue, restricting timely diagnosis and effective management of sciatica. Enhancing public knowledge about sciatica and improving healthcare infrastructure is crucial to alleviating this restraint. By fostering greater awareness and accessibility, the market can better serve individuals in need and contribute to improved health outcomes for sciatica patients.

Market Trends of the Global Sciatica Market

A prominent trend in the global sciatica market is the rising preference for minimally invasive procedures to address sciatic pain. Treatments such as endoscopic discectomy and percutaneous decompression are increasingly favored over traditional surgeries due to their numerous advantages, including smaller incisions, decreased tissue damage, and shortened recovery times. This shift is largely driven by patient demand for quicker rehabilitation and better overall outcomes, alongside a notable reduction in the risk of complications often associated with invasive surgeries. Consequently, both healthcare providers and patients are gravitating towards these innovative, less invasive options, significantly propelling growth in the global sciatica market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Technology Assessment
• Patent Analysis

Global Sciatica Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Acute Sciatica
• Chronic Sciatica
• Others

Global Sciatica Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Nonsteroidal Anti-Inflammatory Drugs
• Oral Steroids
• Anticonvulsant Agents
• Tricyclic Antidepressants
• Opioid Analgesics
• Others

Global Sciatica Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Sciatica Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Sciatica Market Size & CAGR (2025-2032)

• North America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynex Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations